ArticleAsian journal of urology2025
Risk factors for symptomatic lymphoceles in patients undergoing robot-assisted radical prostatectomy with pelvic lymph node dissection: What we learned after more than 350 cases.
Article in Asian journal of urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Sigmoid colon fistulization of an infected pelvic lymphocele after pelvic lymphadenectomy: a case report.Journal of surgical case reports · 2026Article
- Association of fluid management during robotic-assisted radical laparoscopic prostatectomy with early surgical clinical outcomes: a risk factor for lymphoceles.Journal of robotic surgery · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: We investigated patients who underwent robot-assisted radical prostatectomy (RARP) with pelvic lymph node dissection (PLND), analyzing the prevalence and risk factors associated with symptomatic lymphoceles (SLCs). Methods: We evaluated 354 consecutive patients who underwent RARP with PLND by our team between June 2016 and December 2022. After analyzing the prevalence of SLCs, patients were divided into two groups, with and without SLCs. The variables were age, body mass index (BMI), prostate-specific antigen, surgery time, blood loss, length of stay, International Society of Urological Pathology score in the pathology, and the number of lymph nodes removed. These variables were compared between these groups using the Chi-square test and Student's Results: The prevalence of SLCs in this sample of patients undergoing RARP with PLND was 2.0% (7/354), which is slightly lower than the minimum rate reported in the literature. In our analysis, BMI ( Conclusion: The prevalence of SLCs in patients undergoing RARP with PLND is approximately 2.0%. Higher BMI, greater number of lymph nodes removed, and longer length of hospital stay are factors associated with the presence of SLCs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.